Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;26(2):326-337.
doi: 10.1007/s12094-023-03266-7. Epub 2023 Jul 4.

Mechanism of action and treatment of type I interferon in hepatocellular carcinoma

Chunxiu Peng  1 , Zhijian Ye  1 , Ying Ju  1 , Xiuxin Huang  1 , Chenjie Zhan  1 , Ke Wei  1 , Zhiyong Zhang  2
Affiliations
Review

Mechanism of action and treatment of type I interferon in hepatocellular carcinoma

Chunxiu Peng et al. Clin Transl Oncol. 2024 Feb.

Abstract

Hepatocellular carcinoma (HCC) caused by HBV, HCV infection, and other factors is one of the most common malignancies in the world. Although, percutaneous treatments such as surgery, ethanol injection, radiofrequency ablation, and transcatheter treatments such as arterial chemoembolization are useful for local tumor control, they are not sufficient to improve the prognosis of patients with HCC. External interferon agents that induce interferon-related genes or type I interferon in combination with other drugs can reduce the recurrence rate and improve survival in HCC patients after surgery. Therefore, in this review, we focus on recent advances in the mechanism of action of type I interferons, emerging therapies, and potential therapeutic strategies for the treatment of HCC using IFNs.

Keywords: Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Interferon-α; Interferon-β; Type I interferon.

PubMed Disclaimer

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN ESTImates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660 . - DOI - PubMed
    1. Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Curr Epidemiol Rep. 2019. https://doi.org/10.1007/s40471-019-00188-3 . - DOI - PubMed - PMC
    1. Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022. https://doi.org/10.1111/liv.15251 . - DOI - PubMed - PMC
    1. Du L, Liu W, Rosen ST, Chen Y. Mechanism of SUMOylation-mediated regulation of type I IFN expression. J Mol Biol. 2023. https://doi.org/10.1016/j.jmb.2023.167968 . - DOI - PubMed
    1. Zhang Z, Urban S. New insights into HDV persistence: the role of interferon response and implications for upcoming novel therapies. J Hepatol. 2021. https://doi.org/10.1016/j.jhep.2020.11.032 . - DOI - PubMed - PMC

Substances